MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 06.11.2023
NanoString Technologies Anteile 2011-2026 | NSTG
Anteile Jährlich NanoString Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.4 M | 45.3 M | 39.1 M | 34.6 M | 27.9 M | 23.7 M | 20.1 M | 19 M | 17.8 M | 7.64 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 46.4 M | 7.64 M | 28.2 M |
Anteile Vierteljährlich NanoString Technologies
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.7 M | 47.4 M | 46.9 M | 46.7 M | 46.5 M | 46.4 M | 46 M | 45.7 M | 45.6 M | 45.3 M | 44.7 M | 44.4 M | 38.1 M | 37.8 M | 37 M | 36.3 M | 35.6 M | 35.2 M | 31.6 M | 30.9 M | 29.4 M | 25.8 M | 25.5 M | 25.4 M | 25.2 M | 22.7 M | 21.6 M | 21.5 M | 19.9 M | 19.8 M | 19.7 M | 19.6 M | 19.4 M | 18.8 M | 18.3 M | 18.3 M | 18.1 M | 18.1 M | 16.9 M | 14.6 M | 14.6 M | 570 K | 537 K | 411 K | 358 K | 338 K | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 47.7 M | 338 K | 27.6 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
244 M | $ 91.21 | 0.03 % | $ 27.2 B | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
131 M | $ 330.79 | 3.74 % | $ 43.3 B |  USA |
 |
BioLineRx Ltd.
BLRX
|
663 M | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
191 M | $ 1.87 | 0.27 % | $ 356 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
11.5 M | $ 0.46 | -13.08 % | $ 5.27 M | Israel |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
CNS Pharmaceuticals
CNSP
|
443 K | $ 2.29 | 1.11 % | $ 1.02 M | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
85.3 M | $ 2.97 | -0.67 % | $ 253 M | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
122 M | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
13.3 M | $ 10.08 | -0.88 % | $ 134 M | USA |
 |
Cardiff Oncology
CRDF
|
66.8 M | $ 1.59 | 0.32 % | $ 106 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Curis
CRIS
|
13.2 M | $ 0.53 | -3.58 % | $ 6.98 M | USA |
 |
Aquestive Therapeutics
AQST
|
107 M | $ 4.1 | -0.85 % | $ 438 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
94.1 M | $ 37.76 | 1.42 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 49.35 | -0.32 % | $ 4.44 B |  Schweiz |
 |
CytomX Therapeutics
CTMX
|
138 M | $ 4.35 | -4.61 % | $ 600 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
6.73 M | $ 0.88 | 2.44 % | $ 5.92 M | USA |
 |
Cue Biopharma
CUE
|
94.7 M | $ 0.17 | -6.06 % | $ 16.1 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
27.4 M | $ 8.24 | 2.55 % | $ 226 M | Israel |
 |
Cyclerion Therapeutics
CYCN
|
2.52 M | $ 4.13 | -32.85 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Daré Bioscience
DARE
|
11.2 M | $ 1.77 | 1.75 % | $ 19.8 M | USA |
 |
DBV Technologies S.A.
DBVT
|
140 M | $ 20.47 | -2.8 % | $ 2.86 B | France |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 31.46 | 1.29 % | $ 2.09 B | USA |
 |
Avenue Therapeutics
ATXI
|
3.13 M | - | -52.27 % | $ 4.45 M | USA |